Categories: Health

VALNEVA Declaration of shares and voting rights: January 31, 2026

VALNEVA

Declaration of shares and voting rights
January 31, 2026
__________________________________________________________________________________________

Company name: VALNEVA
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon
Regulated market of Euronext Paris – Compartment B

Declaration date: February 6, 2026

Number of shares
composing the share capital of Valneva
Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 

173,877,420

ordinary shares with a par value of €0.15 each

189,607,235 Double voting rights granted on 890 ordinary shares

Transfer into bearer form of 159,714 shares with double voting rights

Exercise of stock options resulting in the issuance of 337,675 new ordinary shares

Between January 8 & January 30, 2026

On January 9, 2026

Between January 12 & January 30, 2026

189,482,913

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
** Net (or exercisable at a General Meeting) voting rights.

GlobeNews Wire

Recent Posts

Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model

A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated…

3 hours ago

Basilea awarded additional CARB-X funding of USD6million to support the clinical development of antibiotic BAL2420

Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million…

3 hours ago

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program…

3 hours ago

World’s First CAR-T Therapy for Solid Tumors Available in China Soon

A New Hope for Patients with Advanced Gastric and Pancreatic CancersSHANGHAI, April 9, 2026 /PRNewswire/…

3 hours ago

Cango Inc. Announces March 2026 Operational Update; Strategically Optimizing Mining Fleet and Improving Production Economics

DALLAS, April 8, 2026 /PRNewswire/ -- Cango Inc. (NYSE: CANG), a leading Bitcoin miner leveraging…

3 hours ago

Rapidise: Powering India’s Next-Generation Electronics Manufacturing Revolution

AHMEDABAD, India and NEW DELHI, April 9, 2026 /PRNewswire/ -- Rapidise, a leading ODM and…

4 hours ago